You are here: Industry Insights > Breast Cancer

News List

FDA agrees to review Roche’s Tecentriq combination for breast cancer pharmaceutical-technology
December 18, 2018
The US Food and Drug Administration (FDA) has accorded priority review status to the supplemental biologics licence application (sBLA) of Roche’s Tecentriq (atezolizumab) as a combination therapy for breast cancer......
Younger Breast Cancer Survivors Suffer More Bone Loss From Treatment drugs
December 12, 2018
Younger breast cancer survivors are at increased risk for osteoporosis -- weak, brittle bones -- due to breast cancer treatments, new study finds.....
Delivering a baby increases, then lowers, risk of breast cancer: Study expressbpd
December 12, 2018
Researchers found that the breast cancer risk peaks 4.6 years after a woman’s most recent birth but then begins to fall
Higher Risk for Breast Cancer After Childbirth May Last 20+ Years drugs
December 11, 2018
The increased risk for breast cancer that occurs after childbirth can last more than 20 years, according to research published online Dec. 11 in the Annals of Internal Medicine.....
Oxybutynin improves quality of life for breast cancer survivors europeanpharmaceuticalreview
December 10, 2018
Oxybutynin could help breast cancer survivors who are affected by increased hot flushes through cancer treatment, improving their quality of life…
Novartis Consistently improved PFS in Patients with PIK3CA Mutated HR+/HER2- Advanced Breast Cancer americanpharmaceuticalreview
December 10, 2018
Novartis today announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with.....
Halaven maker Eisai launches metastatic breast cancer story-sharing campaign fiercepharma
December 10, 2018
Metastatic breast cancer (MBC) can make patients feel isolated, and that’s the feeling Eisai is working to combat with its latest awareness campaign.
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery pharmatimes
December 07, 2018
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint europeanpharmaceuticalreview
December 06, 2018
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer…
New potential breast cancer drug identified expressbpd
December 06, 2018
The new compound is a potential highly effective, next-line treatment

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page